Clinical Trials
1,067 trialsPomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
The First Affiliated Hospital of Soochow University
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
City of Hope Medical Center
huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
University of Pennsylvania
FERTILymph
University Hospital, Lille
Epcoritamab and Rituximab for First-line Follicular Lymphoma
Dana-Farber Cancer Institute
TAB
University of Cincinnati
HEMO-CONNECT
Centre Hospitalier de la côte Basque
PAPE-MID
Inonu University
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Memorial Sloan Kettering Cancer Center
0150-24 SOR
Soroka University Medical Center
CUREMZL002
Institute of Hematology & Blood Diseases Hospital, China
Administration of Repurposed Ketoconazole in Glioma Patients
Universitas Padjadjaran
PBID-12
Burdur Mehmet Akif Ersoy University
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma
University of Washington
ZGR in TN FL
Institute of Hematology & Blood Diseases Hospital, China
RITALLO
University Hospital, Bordeaux
Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies
University of Washington
CD70-targeted immunoPET Imaging of Malignant Cancers
RenJi Hospital
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
University of Washington
Family-Focused Study to Support Medication for Opioid Use Disorder
University of Wisconsin, Madison
SevAsthma
Assistance Publique - Hôpitaux de Paris
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
REFRACT
University of Birmingham
Lenalidomide and Epcoritamab for the Treatment of Previously Untreated Follicular Lymphoma
City of Hope Medical Center
VR&depression
Sykehuset Innlandet HF
Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma
City of Hope Medical Center
Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma
Mayo Clinic
Cannabis Use Disorder Treatment Study
The University of Tennessee, Knoxville
PAM-II
University Medical Center Groningen
CUB-HS2025
Jacobs University Bremen gGmbH
Echo Prompts
Ottawa Heart Institute Research Corporation
Clinical Trial of Lyophilized Powder for Inhalation of Recombinant Human Keratinocyte Growth Factor-2 (Rh-KGF-2) in The Treatment of Patients With Acute Respiratory Distress Syndrome
Shanghai Zhongshan Hospital
Brain Health Together: A Live-Streaming Group-Based Digital Program
University of California, San Francisco
Narrative Exposure Therapy for Adults With an Intellectual Disability
University of Nottingham
CUREFL03
Institute of Hematology & Blood Diseases Hospital, China
Decision Making Tool for Firearm Storage
University of Washington
Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma
City of Hope Medical Center
PNOC020
University of Florida
FLOURISH
Sun Yat-sen University
AG-120 in People With IDH1 Mutant Chondrosarcoma
Memorial Sloan Kettering Cancer Center
EXHITENTRE
Hennepin Healthcare Research Institute
Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)
Sun Yat-sen University
Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma
Washington University School of Medicine
A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
University of Washington
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
GAZAI
Heidelberg University
CAREGIVERSPRO
University Hospital, Rouen